Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Weakly immunogenic CRISPR therapies.

Wilson EA, Anderson KS.

Nat Biomed Eng. 2019 Oct;3(10):761-762. doi: 10.1038/s41551-019-0463-7. No abstract available.

PMID:
31591524
2.

Structure activity relationship towards design of cryptosporidium specific thymidylate synthase inhibitors.

Czyzyk DJ, Valhondo M, Deiana L, Tirado-Rives J, Jorgensen WL, Anderson KS.

Eur J Med Chem. 2019 Sep 4;183:111673. doi: 10.1016/j.ejmech.2019.111673. [Epub ahead of print]

PMID:
31536894
3.

Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival.

Ertz-Archambault NM, Rogoff LB, Kosiorek HE, Ernst BJ, Anderson KS, Pockaj BA, Gray RJ, Northfelt DW.

Support Care Cancer. 2019 Aug 11. doi: 10.1007/s00520-019-05013-7. [Epub ahead of print]

PMID:
31402403
4.

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, Chin SF, Farooq M, Mejia R, Cronin PA, Anderson KS, Kosiorek HE, Northfelt DW, McCullough AE, Patel BK, Weitzel JN, Slavin TP, Caldas C, Pockaj BA, Murtaza M.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaax7392. doi: 10.1126/scitranslmed.aax7392.

PMID:
31391323
5.
6.

The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study.

Campos-Romero A, Anderson KS, Longatto-Filho A, Luna-Ruiz Esparza MA, Morán-Portela DJ, Castro-Menéndez JA, Moreno-Camacho JL, Calva-Espinosa DY, Acosta-Alfaro MA, Meynard-Mejía FA, Muñoz-Gaitán M, Alcántar-Fernández J.

Sci Rep. 2019 Jul 12;9(1):10094. doi: 10.1038/s41598-019-46543-8.

7.

Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.

Sasaki T, Gannam ZTK, Kudalkar SN, Frey KM, Lee WG, Spasov KA, Jorgensen WL, Anderson KS.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2182-2188. doi: 10.1016/j.bmcl.2019.06.047. Epub 2019 Jun 26.

PMID:
31281023
8.

Understanding the structural basis of species selective, stereospecific inhibition for Cryptosporidium and human thymidylate synthase.

Czyzyk DJ, Valhondo M, Jorgensen WL, Anderson KS.

FEBS Lett. 2019 Aug;593(15):2069-2078. doi: 10.1002/1873-3468.13474. Epub 2019 Jun 18.

PMID:
31172516
9.

Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV.

Kudalkar SN, Ullah I, Bertoletti N, Mandl HK, Cisneros JA, Beloor J, Chan AH, Quijano E, Saltzman WM, Jorgensen WL, Kumar P, Anderson KS.

Antiviral Res. 2019 Jul;167:110-116. doi: 10.1016/j.antiviral.2019.04.010. Epub 2019 Apr 26.

PMID:
31034849
10.

Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes.

Ferdosi SR, Ewaisha R, Moghadam F, Krishna S, Park JG, Ebrahimkhani MR, Kiani S, Anderson KS.

Nat Commun. 2019 Apr 23;10(1):1842. doi: 10.1038/s41467-019-09693-x.

11.

Novel allosteric covalent inhibitors of bifunctional Cryptosporidium hominis TS-DHFR from parasitic protozoa identified by virtual screening.

Ruiz V, Czyzyk DJ, Valhondo M, Jorgensen WL, Anderson KS.

Bioorg Med Chem Lett. 2019 Jun 1;29(11):1413-1418. doi: 10.1016/j.bmcl.2019.03.022. Epub 2019 Mar 20.

PMID:
30929953
12.

HPV: Immunology lessons from an ancient oncotarget.

Krishna S, Anderson KS.

Oncotarget. 2019 Feb 12;10(13):1269-1270. doi: 10.18632/oncotarget.26606. eCollection 2019 Feb 12. No abstract available.

13.

The neoepitope landscape of breast cancer: implications for immunotherapy.

Narang P, Chen M, Sharma AA, Anderson KS, Wilson MA.

BMC Cancer. 2019 Mar 4;19(1):200. doi: 10.1186/s12885-019-5402-1.

14.

Tripled yield in direct-drive laser fusion through statistical modelling.

Gopalaswamy V, Betti R, Knauer JP, Luciani N, Patel D, Woo KM, Bose A, Igumenshchev IV, Campbell EM, Anderson KS, Bauer KA, Bonino MJ, Cao D, Christopherson AR, Collins GW, Collins TJB, Davies JR, Delettrez JA, Edgell DH, Epstein R, Forrest CJ, Froula DH, Glebov VY, Goncharov VN, Harding DR, Hu SX, Jacobs-Perkins DW, Janezic RT, Kelly JH, Mannion OM, Maximov A, Marshall FJ, Michel DT, Miller S, Morse SFB, Palastro J, Peebles J, Radha PB, Regan SP, Sampat S, Sangster TC, Sefkow AB, Seka W, Shah RC, Shmyada WT, Shvydky A, Stoeckl C, Solodov AA, Theobald W, Zuegel JD, Johnson MG, Petrasso RD, Li CK, Frenje JA.

Nature. 2019 Jan;565(7741):581-586. doi: 10.1038/s41586-019-0877-0. Epub 2019 Jan 30.

PMID:
30700868
15.

APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.

Cannataro VL, Gaffney SG, Sasaki T, Issaeva N, Grewal NKS, Grandis JR, Yarbrough WG, Burtness B, Anderson KS, Townsend JP.

Oncogene. 2019 May;38(18):3475-3487. doi: 10.1038/s41388-018-0657-6. Epub 2019 Jan 15.

16.

Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy.

Wilson EA, Anderson KS.

Expert Rev Proteomics. 2018 Dec;15(12):1065-1077. doi: 10.1080/14789450.2018.1545578. Epub 2018 Nov 14. Review.

PMID:
30408427
17.

The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.

Ryan MR, Sohl CD, Luo B, Anderson KS.

Mol Cancer Res. 2019 Feb;17(2):532-543. doi: 10.1158/1541-7786.MCR-18-0429. Epub 2018 Sep 26.

PMID:
30257990
18.

DRONE: Direct Tracking of DNA Cytidine Deamination and Other DNA Modifying Activities.

Sasaki T, Kudalkar SN, Bertoletti N, Anderson KS.

Anal Chem. 2018 Oct 16;90(20):11735-11740. doi: 10.1021/acs.analchem.8b01405. Epub 2018 Sep 28.

19.

A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment.

Henderson MC, Silver M, Tran Q, Letsios EE, Mulpuri R, Reese DE, Lourenco AP, LaBaer J, Anderson KS, Alpers J, Costantini C, Rohatgi N, Ali H, Baker K, Northfelt DW, Ghosh K, Grobmyer SR, Polen W, Wolf JK.

Clin Cancer Res. 2019 Jan 1;25(1):142-149. doi: 10.1158/1078-0432.CCR-18-0843. Epub 2018 Sep 5.

PMID:
30185421
20.

Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer.

Krishna S, Ulrich P, Wilson E, Parikh F, Narang P, Yang S, Read AK, Kim-Schulze S, Park JG, Posner M, Wilson Sayres MA, Sikora A, Anderson KS.

Cancer Res. 2018 Nov 1;78(21):6159-6170. doi: 10.1158/0008-5472.CAN-18-0163. Epub 2018 Aug 28.

PMID:
30154146
21.

Reply to Pandey et al.: Understanding the efficacy of a potential antiretroviral drug candidate in humanized mouse model of HIV infection.

Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P, Jorgensen WL, Anderson KS.

Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8114-E8115. doi: 10.1073/pnas.1810136115. Epub 2018 Aug 10. No abstract available.

22.

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.

Barrett MT, Lenkiewicz E, Malasi S, Basu A, Yearley JH, Annamalai L, McCullough AE, Kosiorek HE, Narang P, Wilson Sayres MA, Chen M, Anderson KS, Pockaj BA.

Breast Cancer Res. 2018 Jul 11;20(1):71. doi: 10.1186/s13058-018-1004-0.

23.

JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.

Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, Niu R, Anderson KS.

Clin Breast Cancer. 2018 Oct;18(5):e1205-e1215. doi: 10.1016/j.clbc.2018.05.006. Epub 2018 May 26. Erratum in: Clin Breast Cancer. 2019 Feb;19(1):87-88.

24.

Platination of cysteine by an epidermal growth factor receptor kinase-targeted hybrid agent.

Yang M, Wu H, Chu J, Gabriel LA, Kim Y, Anderson KS, Furdui CM, Bierbach U.

Chem Commun (Camb). 2018 Jul 11;54(54):7479-7482. doi: 10.1039/c8cc04251a. Epub 2018 Jun 19.

PMID:
29915817
25.

A compact, low-cost, quantitative and multiplexed fluorescence detection platform for point-of-care applications.

Obahiagbon U, Smith JT, Zhu M, Katchman BA, Arafa H, Anderson KS, Blain Christen JM.

Biosens Bioelectron. 2018 Oct 15;117:153-160. doi: 10.1016/j.bios.2018.04.002. Epub 2018 Apr 4.

26.

Eccrine Sweat as a Biofluid for Profiling Immune Biomarkers.

Katchman BA, Zhu M, Blain Christen J, Anderson KS.

Proteomics Clin Appl. 2018 Nov;12(6):e1800010. doi: 10.1002/prca.201800010. Epub 2018 Jun 28.

27.

An Automated Microfluidic Assay for Photonic Crystal Enhanced Detection and Analysis of an Antiviral Antibody Cancer Biomarker in Serum.

Race CM, Kwon LE, Foreman MT, Huang Q, Inan H, Kesiraju S, Le P, Lim SJ, Smith AM, Zangar RC, Demirci U, Anderson KS, Cunningham BT.

IEEE Sens J. 2018 Feb 15;18(4):1464-1473. doi: 10.1109/JSEN.2017.2777529. Epub 2017 Nov 24.

28.

Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer: Methodologic issues.

Anderson KS, Mork J, Langseth H, Wallstrom G.

Oral Oncol. 2018 May;80:93. doi: 10.1016/j.oraloncology.2018.02.013. Epub 2018 Mar 30. No abstract available.

PMID:
29606498
29.

Insights into DNA substrate selection by APOBEC3G from structural, biochemical, and functional studies.

Ziegler SJ, Liu C, Landau M, Buzovetsky O, Desimmie BA, Zhao Q, Sasaki T, Burdick RC, Pathak VK, Anderson KS, Xiong Y.

PLoS One. 2018 Mar 29;13(3):e0195048. doi: 10.1371/journal.pone.0195048. eCollection 2018.

30.

Activity and fidelity of human DNA polymerase α depend on primer structure.

Baranovskiy AG, Duong VN, Babayeva ND, Zhang Y, Pavlov YI, Anderson KS, Tahirov TH.

J Biol Chem. 2018 May 4;293(18):6824-6843. doi: 10.1074/jbc.RA117.001074. Epub 2018 Mar 19.

31.

Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.

Kaaks R, Fortner RT, Hüsing A, Barrdahl M, Hopper M, Johnson T, Tjønneland A, Hansen L, Overvad K, Fournier A, Boutron-Ruault MC, Kvaskoff M, Dossus L, Johansson M, Boeing H, Trichopoulou A, Benetou V, La Vecchia C, Sieri S, Mattiello A, Palli D, Tumino R, Matullo G, Onland-Moret NC, Gram IT, Weiderpass E, Sánchez MJ, Navarro Sanchez C, Duell EJ, Ardanaz E, Larranaga N, Lundin E, Idahl A, Jirström K, Nodin B, Travis RC, Riboli E, Merritt M, Aune D, Terry K, Cramer DW, Anderson KS.

Int J Cancer. 2018 Aug 1;143(3):515-526. doi: 10.1002/ijc.31335. Epub 2018 Mar 8.

32.

From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.

Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P, Jorgensen WL, Anderson KS.

Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E802-E811. doi: 10.1073/pnas.1717932115. Epub 2017 Dec 26. Erratum in: Proc Natl Acad Sci U S A. 2018 Mar 12;:.

33.

Modeling the Subclonal Evolution of Cancer Cell Populations.

Chowell D, Napier J, Gupta R, Anderson KS, Maley CC, Sayres MAW.

Cancer Res. 2018 Feb 1;78(3):830-839. doi: 10.1158/0008-5472.CAN-17-1229. Epub 2017 Nov 29.

34.

Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Ferdosi S, Rehder DS, Maranian P, Castle EP, Ho TH, Pass HI, Cramer DW, Anderson KS, Fu L, Cole DEC, Le T, Wu X, Borges CR.

J Proteome Res. 2018 Jan 5;17(1):543-558. doi: 10.1021/acs.jproteome.7b00672. Epub 2017 Nov 21.

35.

Serum Immune Profiling for Early Detection of Cervical Disease.

Ewaisha R, Panicker G, Maranian P, Unger ER, Anderson KS.

Theranostics. 2017 Aug 23;7(16):3814-3823. doi: 10.7150/thno.21098. eCollection 2017.

36.

Discussion of: "The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review".

Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Tolgay Ocal I, Pockaj BA.

Am J Surg. 2017 Dec;214(6):1102-1103. doi: 10.1016/j.amjsurg.2017.09.024. Epub 2017 Sep 30. No abstract available.

PMID:
29037421
37.

The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review.

Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, Anderson KS, McCullough AE, Ocal IT, Pockaj BA.

Am J Surg. 2017 Dec;214(6):1096-1101. doi: 10.1016/j.amjsurg.2017.08.024. Epub 2017 Sep 18.

PMID:
28943062
38.

Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer.

Anderson KS, Wallstrom G, Langseth H, Posner M, Cheng JN, Alam R, Chowell D, Furre IE, Mork J.

Oral Oncol. 2017 Oct;73:132-137. doi: 10.1016/j.oraloncology.2017.08.014. Epub 2017 Sep 1.

39.

Classifying the evolutionary and ecological features of neoplasms.

Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D.

Nat Rev Cancer. 2017 Oct;17(10):605-619. doi: 10.1038/nrc.2017.69. Epub 2017 Sep 15. Review.

40.

Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer.

Dahlstrom KR, Anderson KS, Field MS, Chowell D, Ning J, Li N, Wei Q, Li G, Sturgis EM.

Cancer. 2017 Dec 15;123(24):4886-4894. doi: 10.1002/cncr.30955. Epub 2017 Sep 12.

41.

Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography.

Chan AH, Lee WG, Spasov KA, Cisneros JA, Kudalkar SN, Petrova ZO, Buckingham AB, Anderson KS, Jorgensen WL.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9725-9730. doi: 10.1073/pnas.1711463114. Epub 2017 Aug 21.

42.

Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.

Chen M, Andreozzi M, Pockaj B, Barrett MT, Ocal IT, McCullough AE, Linnaus ME, Chang JM, Yearley JH, Annamalai L, Anderson KS.

Mod Pathol. 2017 Nov;30(11):1516-1526. doi: 10.1038/modpathol.2017.86. Epub 2017 Jul 28.

43.

Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies.

Inan H, Wang S, Inci F, Baday M, Zangar R, Kesiraju S, Anderson KS, Cunningham BT, Demirci U.

Sci Rep. 2017 Jun 12;7(1):3322. doi: 10.1038/s41598-017-02672-6.

44.

Notes from the Field: Veillonella Misidentified as Francisella tularensis - Idaho, 2016.

Carter KK, Peterson EM, Voermans RL, Anderson KS 3rd, Cox T, Kassem AM, Ball CL, Hahn CG.

MMWR Morb Mortal Wkly Rep. 2017 Jun 2;66(21):564-565. doi: 10.15585/mmwr.mm6621a4. No abstract available.

45.

MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma.

Panaccione A, Zhang Y, Ryan M, Moskaluk CA, Anderson KS, Yarbrough WG, Ivanov SV.

Stem Cell Res. 2017 May;21:160-166. doi: 10.1016/j.scr.2017.05.002. Epub 2017 May 5.

46.

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.

Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.

47.

Autoantibody biomarkers for the detection of serous ovarian cancer.

Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW, Anderson KS.

Gynecol Oncol. 2017 Jul;146(1):129-136. doi: 10.1016/j.ygyno.2017.04.005. Epub 2017 Apr 18.

48.

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.

Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD.

Cancer Biomark. 2017;19(2):129-136. doi: 10.3233/CBM-160071.

PMID:
28387659
49.

Understanding the molecular mechanism of substrate channeling and domain communication in protozoal bifunctional TS-DHFR.

Anderson KS.

Protein Eng Des Sel. 2017 Mar 1;30(3):253-261. doi: 10.1093/protein/gzx004. Review.

50.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

Supplemental Content

Loading ...
Support Center